Proteomics

Dataset Information

0

KMT2A rearranged B lineage infant ALL cell line SEM treated with bortezomib LC-MS/MS


ABSTRACT: The KMT2A rearranged B lineage infant ALL cell line SEM was treated with the proteasome inhibitor bortezomib followed by a multiplexed mass spectrometry-based proteomic analysis at multiple time points (0, 6, 12, 16, and 20 hours) over 20 hours to further understand the cellular response of these cells to proteasome inhibition.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Vishwajeeth Pagala  

LAB HEAD: Tanja A. Gruber

PROVIDER: PXD038845 | Pride | 2023-02-15

REPOSITORIES: Pride

altmetric image

Publications


Rearrangments in Histone-lysine-N-methyltransferase 2A (KMT2Ar) are associated with pediatric, adult and therapy-induced acute leukemias. Infants with KMT2Ar acute lymphoblastic leukemia (ALL) have a poor prognosis with an event-free-survival of 38%. Herein we evaluate 1116 FDA approved compounds in primary KMT2Ar infant ALL specimens and identify a sensitivity to proteasome inhibition. Upon exposure to this class of agents, cells demonstrate a depletion of histone H2B monoubiquitination (H2Bub1  ...[more]

Similar Datasets

2020-11-09 | PXD017503 | Pride
2020-05-26 | PXD016197 | Pride
2014-09-16 | E-GEOD-61416 | biostudies-arrayexpress
2010-05-07 | E-GEOD-21504 | biostudies-arrayexpress
2011-03-23 | E-GEOD-28131 | biostudies-arrayexpress
2015-09-04 | E-GEOD-71145 | biostudies-arrayexpress
2015-09-04 | GSE71145 | GEO
2009-04-29 | E-GEOD-5073 | biostudies-arrayexpress
| PRJNA640535 | ENA
2008-06-14 | GSE11771 | GEO